Please login to the form below

Not currently logged in
Email:
Password:

Boston Biomedical appoints commercial head

Patricia Andrews joins from Incyte Corporation

Boston Biomedical has named Pfizer veteran Patricia Andrews as chief commercial officer.

Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic colorectal cancer.

She previously spent 17 years at Pfizer, rising to VP and general manager of US oncology, before joining from oncology/inflammation-focused Incyte Corporation where she served as executive VP and chief commercial officer.

At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.

Andrews is expected to perform a similar role at Boston, which has so far been focused on research.

"I am very excited about this opportunity and look forward to building a world-class commercial oncology team at Boston Biomedical," she said.

21st November 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics